You are here

  • Home
  • Archive
  • Volume 12, Issue 5
  • Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study

Article metrics

Article menu

Download PDFPDF

Clinical/translational cancer immunotherapy
Original research
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study

 

Online download statistics by month:

Online download statistics by month: May 2024 to January 2026

AbstractFullPdf
May 202454556
Jun 2024559567158
Jul 202449149231
Aug 202421321496
Sep 2024218221117
Oct 202424925582
Nov 2024251256130
Dec 2024368375132
Jan 2025316316135
Feb 2025328328116
Mar 2025252255154
Apr 2025192195105
May 202519419490
Jun 202510911249
Jul 2025110
Aug 2025110
Jan 2026001
Total379638371402